Drug delivery to the inner ear is an ideal method to treat a wide variety of otologic conditions. A broad range of potential applications is just beginning to be explored. New approaches combine principles of inner ear pharmacokinetics with emerging technologies of drug delivery including novel delivery systems, drug-device combinations, and new categories of drugs. Strategies include cell-specific targeting, manipulation of gene expression, local activation following systemic delivery, and use of stem cells, viral vectors, and gene editing systems. Translation of these therapies to the clinic remains challenging given the potential risks of intracochlear and intralabyrinthine trauma, our limited understanding of the etiologies of particular inner ear disorders, and paucity of accurate diagnostic tools at the cellular level. This review provides an overview of future methods, delivery systems, disease targets, and clinical considerations required for translation to clinical medicine.
Introduction
The delivery of reagents to accomplish inner ear therapy has been utilized for decades in the clinical environment, particularly with transtympanic injections delivered to the middle ear space to facilitate diffusion across the round window membrane into the cochlea. With the advent of the cochlear implant, intracochlear access has been frequently performed in humans via round window or basal turn cochleostomy. In animal models such as the guinea pig that provide easier access to various portions of the inner ear, additional routes of delivery have been explored, including a comparison of round window injections versus placement of drug-delivering materials on the surface of the round window membrane, intracochlear injections to the base, apex, or deep into the scala tympani, and intralabyrinthine injections to the semicircular canal or vestibule (Salt and Plontke, 2009 ). In developing new inner ear therapies, the potential effect of the location of delivery on drug efficacy must be balanced against the risks of delivery to that location. In this review, additional potential methods of delivery will be discussed including scala media delivery, systemic delivery with local activation, and methods to mitigate risks of intracochlear and intralabyrinthine access by using automated systems such as robotic surgery and micro-infusion pumps.
Current reagents for inner ear therapy in the clinic primarily consist of pharmaceuticals such as aminoglycosides and steroids. However, in the laboratory where future therapies are being developed, many other reagents have been explored, including neurotrophins, small molecule drugs, small interfering RNA (siRNA), gene editing reagents, and viral vectors. The proposed treatments have been aimed at a wide variety of targets in the inner ear such as epithelial cells, neurons, glia, connective tissue, infectious pathogens, and immune-mediating cells. Many of these reagents await translation to the clinic, and are discussed in further detail below.
Future methods of delivery

Alternative routes of delivery
Much of the experimental work on inner ear drug delivery has been carried out in animal models. Each species has its own anatomical features, posing unique drug delivery possibilities and challenges. The inner ear of humans is larger than that of rodents commonly used in research, making some aspects of approach and injection easier. However, rodents such as guinea pigs and chinchillas have a much more accessible cochlea because the otic capsule protrudes into the middle ear space and is easily visualized when the middle ear is accessed.
Reagents placed into endolymph in the scala media are in direct contact with the luminal surfaces of the epithelial cells lining the cochlear duct including hair cells, supporting cells, and marginal cells of the stria vascularis. Several laboratories have obtained data in animal models demonstrating that adenovirus viral vectors injected into perilymph do not express reporter genes in the epithelium of the cochlear duct (Excoffon et al., 2006; Ishimoto et al., 2002; Venail et al., 2007) . In contrast, when injected into the scala media, robust gene expression is seen in supporting cells of the mature ear (Atkinson et al., 2014; Ishimoto et al., 2002; Kawamoto et al., 2003a; Sheffield et al., 2011; Venail et al., 2007) .
Supporting cells are endogenous cells that can transdifferentiate into new hair cells following depletion of the original hair cells, a process that occurs spontaneously in the hearing sensory epithelium of all vertebrates other than mammals (Brignull et al., 2009) , and can be induced to transdifferentiate by manipulating gene expression in the living mammalian cochlea (Atkinson et al., 2014; Kawamoto et al., 2003a; Mizutari et al., 2013) . This potential to manipulate gene expression in supporting cells is currently the most important rationale for injecting into the scala media, but access to the scala media in the human ear is difficult with current technology. Implementation and optimization of robotic surgery using personalized cochlear anatomic maps may make scala media injection feasible in the future.
Systemic delivery with local activation
For ease of delivery, it would be optimal if a therapeutic reagent could be given systemically, reach the ear at the same concentration as other organs, and yet act in the ear only. Dedicated research effort is needed to advance delivery technology in this direction, as currently this option has not yet been developed. For instance, earspecific activation following systemic delivery could conceivably be achieved by harnessing features specific to the ear to activate or induce release of the active ingredients of therapeutic molecules. One specific ear feature is the unique chemical composition of endolymph characterized by high concentration of potassium and 80 mV positive direct current potential, which is not found elsewhere in the body. Should medicinal chemistry succeed in designing a compound that becomes active when immersed in such a fluid, it should be possible to accomplish ear-specific activation. Another feature of the ear is its ability to receive high intensity acoustic energy. With amplification provided by the ossicles in the middle ear, it is possible to vibrate the inner ear fluids at a specific frequency with high intensity acoustic signal, potentially leading to the activation of reagents designed for activation by such a physical phenomenon. Advances in the design of bioactive molecules may accomplish these tasks and provide ear-specific therapy following systemic administration. Such reagents are not currently available to our knowledge, but could be developed using advanced medicinal chemistry and related fields of research.
Specific delivery methods also will be needed to improve outcomes of cochlear implants. Cochlear implants are very successful and useful, but some of their features could still be improved. The two most important limitations are low speech intelligibility in noisy environments, and lack of music appreciation (Kohlberg et al., 2014; Zeitler et al., 2008) . These limitations are partly due to the current spread of each electrode, resulting in relatively low signal quality (Caldwell et al., 2017) . One way to address these limitations is to increase the number of stimulating channels via use of light instead of electric stimulation with optogenetics, whereby lightsensitive channel proteins are inserted into the auditory nerve and photons are converted to trigger a neural impulse. Unlike electrical fields that spread in all directions, light can be directed and even focused. Therefore, light stimulation can gain a significantly increased number of independent stimulating sites with high spatial resolution.
The field of optogenetics uses channelrhodopsins which are green algae photoconverting proteins, and other similar proteins (Cho and Li, 2016) . The channels would need to be expressed in spiral ganglion neurons (SGNs), which could be accomplished by insertion with a viral vector. Preliminary data show the feasibility of optical stimulation of the auditory nerve in the deafened rodent cochlea genetically modified to express a channelrhodopsin (Moser, 2015; Richter et al., 2013) . Future enhancement in gene transfection technology and improvement in the design of more efficient light sources and sound-to-light algorithms will likely improve optogenetic technology, leading to enhanced outcomes of cochlear implantation. It appears that optical stimulation has the potential to target narrowly defined SGN populations, which would allow a much higher number of independent stimulation channels (Hernandez et al., 2014) . While this optogenetic technology holds promise for creating an improved cochlear implant of the future, improved delivery methods for inserting the channelrhodopsins or other transgenes into SGNs and assuring long term gene expression will be necessary prior to transition into clinical settings.
3. Future drug delivery and targeting systems 3.1. Cell-specific targeting via gene expression Manipulation of gene expression can be used to accomplish several potential goals through up-or down-regulation of expression. The goals of such manipulations include protection, repair, and regeneration of specific cell types and functions. In all cases it is necessary to verify that potential side effects, listed in a later section of this review, would not be greater than the potential benefit. Once the therapeutic reagent is in the inner ear, it is necessary to target its expression or activity to a specific type of cells. If the delivery shuttle is a viral vector, specificity can be accomplished by tropism of the virus to a specific cell type, and/or by using cellspecific promoters to drive expression. Small interfering RNA (siRNA) reagents are also useful for blocking expression of specific genes to accomplish therapeutic goals related to dominant negative mutations (Maeda et al., 2005) , or to manipulate pathways for enhancing hair cell regeneration (Jung et al., 2013) . siRNA reagents currently lack some of the specificity of viruses, but the ability to deliver these reagents using a virus may partly resolve this limitation.
The condition of cells in the inner ear also needs to be considered when designing therapies. Deaf ears or ears with partial pathology such as incomplete or localized hair cell loss may not necessarily respond to the presence of viruses in the same way as normal ears. Experimental animal models will need to be used to characterize and optimize delivery vehicles, cell specificity and side effects, along with efficacy and outcomes for addressing different stages of pathology.
Recent advances in understanding epigenetic changes in chromatin in general (Teschendorff and Relton, 2018) and in the inner ear (Doetzlhofer and Avraham, 2017; Layman and Zuo, 2014) increase and enhance the arsenal of possibilities for therapy, as seen by recent data on the protective effects of chromatin remodeling (Chen et al., 2009 (Chen et al., , 2016 He et al., 2015) . Future ability to reverse epigenetic modifications could enhance the responsiveness of cells to exogenous reagents by revealing desirable binding sites on the chromatin. Such approaches could benefit attempts to induce regeneration or to correct mutations using phenotypic rescue approaches.
Increasing viral vector specificity
In many cases, viral vectors are the most efficient gene transfer shuttles, and their cell-specific uptake can be tailored to some extent (Heilbronn and Weger, 2010) . A variety of viral vectors have been used in animal models for inner ear therapy. These include adeno-associated virus (AAV), bovine adeno-associated virus, lentivirus, adenovirus, and others, as recently reviewed Sacheli et al., 2013) . Several aspects of viral gene transfer need further study to advance their translation to clinical applicability. One major task is to establish whether data obtained using rodent animal models translates to the human ear. Moving experimentation to primates will be an important step in this process. Even as studies in primates advance toward human applications, experiments in rodents and other animals will remain useful for first-line assessments of novel gene transfer methods.
The longevity and turnover of target cells also needs to be considered in further detail. For instance, a study evaluating the overexpression of neurotrophic factors for enhancing spiral ganglion survival and sprouting revealed that neurotrophin levels declined weeks after AAV injection , possibly due to death of mesothelial cells infected by the virus. Targeting cell populations with low turnover may enhance long-term gene expression when it is needed, particularly for maintaining specific cell populations or for gene replacement therapy in cases of genetic deafness.
The immune response to the vector is another important aspect of viral-mediated gene delivery. Animals in the laboratory are usually specific pathogen free, namely, they have not been previously exposed to viruses, unlike most humans who are the targets for viral therapy. For safe therapy, most viruses used as gene delivery vectors in the laboratory must be engineered to reduce the severity of the immune response they elicit. AAV vectors may represent an exception due to their theoretically less severe immune response, as they appear to be well tolerated in the visual system (Simonelli et al., 2010) and are likely to also be successful in the human therapy in the ear and other organs (Kay, 2015) .
AAV vectors injected into the perilymph of animal models lead to gene expression in epithelial cells of the cochlear duct, and transfected cells are usually hair cells (Konishi et al., 2008; Lalwani et al., 1996; Shibata et al., 2009; Stone et al., 2005) . Therefore, hair cell-specific therapies are feasible, especially for curing genetic diseases involving hair cell mutations, as has been recently shown in several mouse models Askew et al., 2015; Isgrig et al., 2017) . One limitation of using AAV vectors for therapy is that their small size limits the genes that can be delivered, but the technology for enhancing the gene load in AAV vectors is rapidly developing, as discussed below. Another area requiring further development is the treatment of adult ears. In most of studies cited above, the virus was injected into immature ears; future experiments will need to extend the feasibility of these treatments to mature ears.
Sequential drug delivery
For some therapeutic goals, it may be necessary to sequentially deliver reagents at different time points. Attempts to induce hair cell regeneration or to implant stem cells and guide their differentiation may require more than one administration of therapeutics. Partial, inefficient regeneration of hair cells has been accomplished with the use of a single agent, as shown in experiments with DAPT, a gamma-secretase inhibitor leading to Notch pathway inhibition (Mizutari et al., 2013) , and Math1 gene transfer via adenovirus, leading to Atoh1 overexpression (Kawamoto et al., 2003a) . It is very likely that combination therapies utilizing more than one reagent with sequential administration will be required to enhance efficacy. To accomplish this, a cannula could be placed in the cochlea and connected to an external pump or injectable reservoir, which would facilitate reloading of reagents. Implanted mini-osmotic pumps may also serve an important purpose for future applications requiring continued or sequential administration of therapeutics.
Manipulation of membranous barriers may enhance penetration and access of therapeutics. Viral vectors placed on the round window membrane do not readily diffuse into perilymph, however partial digestion of the round window membrane facilitates AAV transfection of inner hair cells in an animal model . Once viral vectors are in perilymph, their access to different cell types, especially those lining the scala media, may still be restricted. Molecules that transiently enhance the permeability of internal cochlear membranes such as Reissner's membrane may be useful for enhancing spread of vectors from the perilymph to target cells in other areas. This could be accomplished by use of sodium hyaluronate (Healon) (Shibata et al., 2012) or by reagents that transiently open adherens junctions (Park et al., 2014) .
Drug-device combination therapy
Combining an implantable device with simultaneous single application drug delivery is a strategy that is already used clinically (Bento et al., 2016) . Access to the cochlea is required for placement of cochlear implants, which concurrently provides an opportunity for additional drug delivery or other procedures directly to the cochlea. Healon and dexamethasone are examples of reagents placed along with the cochlear implant electrode. Implants eluting dexamethasone have been tested in animals and found to be effective in reducing fibrosis and impedance as compared to controls (Wilk et al., 2016) . As such, these implants are likely to be transitioning to clinical trials in the near future for longer-term secretion into perilymph. Future treatments may include other reagents that can enhance the biological substrate of the ear that receives the implant. The main goals would be to enhance preservation of SGNs and to induce sprouting of neurons to an area closer to the electrodes. Experiments in animals show efficacy of treatment with neurotrophins, but variability in outcomes is a limitation (Pfingst et al., , 2017 Ramekers et al., 2015; Wise et al., 2010 Wise et al., , 2011 . Use of viruses for overexpression may also have to await further improvement in vector technology. Further, a better understanding of the site of depolarization elicited by electrical stimulation will help to determine the importance of neurite sprouting in the direction of the cochlear implant electrode. Preliminary results on the improvement of several objective measurable parameters in guinea pigs provide rationale for proceeding with this approach (Pfingst et al., 2017) .
Recent data on combining cochlear implantation with plasmidbased transgene expression of neurotrophins provides a potentially useful non-viral method for gene delivery (Pinyon et al., 2014) . In these studies, the implant electrode was used for delivering electroporation current, facilitating uptake of naked DNA by cochlear cells and leading to neurotrophin overexpression.
In the more distant future, it is feasible that patients will be able to self-regulate therapy into the ear. When efficacious and safe treatments for tinnitus, M eni ere's disease, and other diseases are available through diffusible reagents, it is conceivable that delivery of therapeutic reagents via a patient-controlled, permanently implanted mini-osmotic pump or other controllable reservoir may become a reality. Therapeutics in such a device could be aimed at changing cochlear fluid pressure, the level of the endocochlear potential, the extent of outer hair cell motility, thresholds of neuronal firing, or the concentration of potassium in the scala media.
Future targets of inner ear therapy
With the advancement of technology to improve the process of drug delivery to the inner ear as well as the ability to target specific cell types, the prospect of treating the underlying causes of otologic and neurotologic diseases becomes more realistic. Several emerging techniques in molecular biology, particularly within the realm of personalized medicine for genetic disorders and neoplasms, can potentially be applied to the inner ear. Here, we review some of these techniques and discuss their application to otologic disease.
Genetic hearing loss
Approximately half of all cases of congenital hearing loss are genetic. Of these, approximately 37% are due to sporadic causes and 63% due to inherited causes (Marazita et al., 1993) . The majority of non-syndromic hearing loss is autosomal recessive, approximately 75e80%; most of the remaining 20e25% are autosomal dominant, and 1e1.5% are X-linked or mitochondrial (Chang, 2015; Kenneson et al., 2002) . Mutations in GJB2 and SLC26A4 are responsible for the majority of autosomal recessive cases, but no single gene has been associated with the majority of autosomal dominant cases.
Current strategies for curing genetic disease include use of embryonic or somatic stem cells, gene transfer, gene editing, and RNA modification (O'Connor and Crystal, 2006) . With increased efficiency of sequencing techniques, as well as the use of preimplantation genetic diagnosis, the correction of underlying genetic mutations to allow for normal protein production will become possible. Gene therapy can in principle involve insertion of a transgene or editing of the existing mutated gene. For the latter case, one emerging area of research involves using the CRISPR-Cas gene editing system to modify gene mutations (Gao et al., 2018; Liang et al., 2015; Ma et al., 2017) ; however, there are still challenges to overcome to ensure that the correct gene is reliably altered without producing off-target mutations or mosaic cell populations within the embryo (Ledford, 2017) .
Fetal gene therapy is another area likely to see development in the near future. Fetal gene therapy will be extremely important for phenotypic rescue in cases where post-natal treatment is too late because the affected gene is required for development and/or because the affected cells die prenatally. Many of the gene transfer experiments conducted on mice carrying a mutant gene are performed on neonatal animals Askew et al., 2015; Isgrig et al., 2017; Yu et al., 2014) ; the equivalent human developmental stage is earlier than mid-gestation. The feasibility of modulating gene transfer at even earlier time points during development has been demonstrated by injections into the mouse otocyst (Bedrosian et al., 2006; Brigande and Heller, 2009; Depreux et al., 2016; Gubbels et al., 2008) . The ability of in utero gene therapy to prevent hearing loss in an affected individual (Miwa et al., 2013 ) provides a strong motivation for continued research in this area.
In addition to the need for further research and development regarding the above techniques, genetic therapies face regulatory, economic, societal, and political barriers given the ethical issues surrounding gene modification of embryos (O'Connor and Crystal, 2006) . These must be addressed prior to broader implementation.
Neoplasms of the temporal bone and lateral cranial base
Neoplasms of the external, middle, and inner ear, as well as the lateral cranial base, can alter or impair hearing and balance and pose other health risks. These tumors are typically treated with a combination of surgical resection, radiotherapy, stereotactic radiosurgery, and chemotherapy. Many benign and malignant neoplastic pathologies can present in this area, including cutaneous squamous cell carcinomas and basal cell carcinomas of the external ear, and squamous cell carcinomas, adenocarcinomas, and endolymphatic sac tumors in the middle and inner ear (Devaney et al., 2005) . Vestibular schwannomas represent the majority of tumors arising within the cerebellopontine angle, and both sporadic and neurofibromatosis type 2 (NF2) cases have been linked to mutations in merlin (also known as schwannomin) (Sughrue et al., 2011) . A better understanding of the molecular biology of vestibular schwannomas, both in the epidemiology of NF2 gene mutations and function of the merlin protein, will assist in the development of targeted therapies to help limit morbidity and address residual disease (Sughrue et al., 2011) . Some of these treatments will necessitate specific delivery methods to facilitate targeted therapy.
In the field of cancer biology in general, significant advances have been made to individualize treatment based on the biology of a patient's particular tumor, with the goal of targeting cancer cells while sparing the patient from side effects that affect normal cells. Immunotherapy and suicide gene therapy are two approaches that can be used to target cancer cells. In the field of immunotherapy, two main approaches have been studied: therapeutic monoclonal antibodies that prevent cancer cells from evading the immune response, and adoptive cell transfer-based immunotherapy to genetically engineer T-cells to attack specific tumor-associated antigens (Khalil et al., 2016; Restifo et al., 2012; Topalian et al., 2016) . The Food and Drug Administration has recently approved monoclonal antibodies that target the immune checkpoints of cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, with promising results in the treatment of advanced-stage melanoma and non-small-cell lung cancer (Khalil et al., 2016; Topalian et al., 2016) . Suicide gene therapy is another approach that targets cancer cells. Vehicles such as viral vectors, liposomes, or nanoparticles can transport suicide-inducing genes to specific cell types via recognition of receptors expressed on cancer cells (Zarogoulidis et al., 2013) . Once delivered to the cell, there are many potential mechanisms of action including silencing gene expression, expression of intracellular antibodies blocking vital cellular pathways, and expression of caspases and deoxyribonucleases. One advantage of these targeted therapies is that they inherently reduce the risk of side effects, allowing systemic administration of higher doses than might otherwise be used, but efficiency may further be improved by local delivery. These therapies have not yet been tested specifically for neoplasms of the inner ear or lateral skull base, but the general strategies appear to be applicable to a broad spectrum of tumors.
Diseases with no clear etiology
There are many otologic and neurotologic disorders with limited pharmaceutical treatment options. Some of these include M eni ere's disease, sudden sensorineural hearing loss, autoimmune inner ear disease, and acute-onset idiopathic facial nerve paralysis. A better understanding of the etiology and/or pathologic processes that drive these diseases is needed to develop targeted therapies. However, because these disorders are localized to the ear, it is feasible that therapy for these conditions will involve one or more of the local delivery methods described above, which will also reduce the risk of systemic side effects. Currently, high-dose oral corticosteroids are frequently prescribed to treat sudden sensorineural hearing loss, M eni ere's disease, autoimmune inner ear disease, and facial nerve paralysis, but these drugs can impose many unwanted systemic side effects including weight gain, hypertension, hyperglycemia, osteoporosis, immunosuppression, and adrenal suppression. Furthermore, systemic therapy is not consistently effective, as is the case with oral corticosteroid therapy. Transtympanic drug delivery has to some extent mitigated systemic toxicities, but its efficacy is also inconsistent. Once appropriate therapeutic targets can be determined, optimal delivery methods can be determined.
Diagnostic limitations and solutions
Diagnostic tools for assessing the condition of the cochlea in humans are limited at present, thereby preventing further development and optimization of therapies. Otoacoustic emissions can disclose if outer hair cell motility is driving the active cochlea normally or not, but in the case of negative results, it is not possible to distinguish whether outer hair cells are absent or dysfunctional. Elevated auditory brainstem response thresholds cannot distinguish between absence or dysfunction of the auditory nerve. Tests to evaluate the condition of the stria vascularis have not yet been developed. Thus, without the ability to ascertain the presence and functionality of hair cells, neurons, or other cells within the cochlea, effective reparative or regenerative therapies will be difficult to develop.
Precision medicine, a constantly evolving and improving medical entity, will likely contribute to improved diagnosis and more personalized treatment that is based on the patient's genetic and genomic profiles, in addition to their symptoms. Tools like the OtoSCOPE at the University of Iowa (Sloan-Heggen and Smith, 2016; Taylor et al., 2013) provide improved diagnosis for identification of mutations involved in hereditary hearing loss. OtoSCOPE now provides comprehensive genetic testing for all genes implicated in non-syndromic hearing loss, some syndromic hearing loss, and Usher mutations. To advance future therapies, additional information will be needed to diagnose the condition of ears with hearing loss due to aging, ototoxicity, acoustic trauma, infections, inflammation, and combinations of these causes. Improved diagnostics will provide much needed detail about the condition of the cochlear tissue as well as providing enhanced guidance for increasing accuracy of delivery and minimizing side effects. Without improved diagnostic tools, it will be difficult to select and implement future therapies for specific ears.
Translation of inner ear drug delivery to clinical application
Access to the inner ear in humans
We provide here a brief summary of current methods used for inner ear drug delivery, leading to a discussion of risks and potential side effects, and future technological advances that could reduce or eliminate these risks. As discussed previously, there are two principal approaches currently employed to access the inner ear for local drug delivery. The first is transtympanic delivery, which is typically performed in an in-office setting using topical anesthesia to the tympanic membrane (TM). Typically, 0.5e1 mL of drug solution is delivered through a small diameter needle through the posterior aspect of the TM to fill the middle ear space, and the solution is allowed to bathe the round window membrane for a period of time by optimizing patient positioning to avoid drug loss through the Eustachian tube. With this method, side effects of delivery are minimized and higher doses of anesthesia are avoided, allowing this procedure to be done on the same day as a clinic visit.
The second method is intracochlear delivery, which is a more involved approach most likely to be done in an operating room under a general or IV sedative anesthetic. After anesthesia has been established, the TM is elevated to access the middle ear space and lateral face of the otic capsule, similar to what is done in a transcanal stapedotomy procedure for otosclerosis. Canalplasty to facilitate additional bone removal from the canal may be required to provide visualization of the otic capsule. This approach would afford access for injecting the drug solution directly into the inner ear through the round window membrane, through the stapes footplate, or potentially through a basal turn cochleostomy. Much smaller volumes of drug solution would be needed for intracochlear delivery than with transtympanic injection. Injection of the drug solution could be performed directly into the cochlear fluids through one of the sites above, or by utilizing a round window membrane microperforator device to enhance drug entry to the cochlea, as effectively demonstrated in laboratory animals (Kelso et al., 2015) . After returning the TM to a normal position, the patient would then be discharged home the same day or after a one-night hospital stay depending on the short-term side effects of the procedure.
Other approaches to the inner ear could be entertained such as a mastoidectomy through a postauricular incision. This type of approach would afford access to various intracochlear locations for injection such as the semicircular canals, vestibule, round window, and different compartments of the cochlea; however, given the additional effort, time, and risk involved, this type of approach seems less likely to be utilized for inner ear drug delivery if one of the above two methods can provide adequate access for delivery.
Both the transtympanic and intracochlear approaches for inner ear drug delivery have short-and long-term risks, as with any procedure. Many of these risks would be common to the two procedures; however, an intracochlear approach would be expected to have more potential side effects. Below we discuss these risks and the management of potential complications.
Potential risks of inner ear drug delivery
Short-term risks include bleeding, infection, TM perforation, facial nerve weakness or paralysis, dysgeusia (taste change), perilymph fistula, vestibular manifestations such as vertigo or dizziness, pain, and ear fullness. Inner ear inflammation, serous labyrinthitis, or reparative granuloma (exaggeration of the normal reparative process) may also occur. Potential long-term risks include hearing loss, vestibulopathy, or leakage of drug into the cerebrospinal and subarachnoid spaces. Such leakage can result in contralateral ear side effects as well as meningitis or encephalitis. Some of these risks could be mitigated by careful pre-procedural clinical examination with otomicroscopy and/or preoperative imaging to ensure normal anatomy and lack of existing TM perforation or middle ear inflammation. The administration of periprocedural Fig. 1 . Light micrographs taken from the base of guinea pig cochleae that were implanted and stimulated without prior deafening (A) or following elimination of the hair cells (B). In both cases, fibrosis is seen in the scala tympani (with permission from JARO, Springer). steroids may help minimize intracochlear trauma and subsequent inflammation, as has been the experience with other inner ear procedural manipulations such as cochlear implantation and stapedotomy procedures (Eastwood et al., 2010; Honeder et al., 2015) .
One common manifestation of adverse reaction of the cochlea to surgical manipulations is growth of connective tissue in the fluid spaces, also known as fibrosis (Fig. 1) . Over many years of experimental procedures performed in our laboratory at Kresge Hearing Research Institute, we noted fibrosis in guinea pig ears following deafening, cochlear implant insertion, electrical stimulation, viral vector injection, and neurotrophin overexpression, alone, or in combination (Kang et al., 2010; Kawamoto et al., 2003b) . The possibility that future methods performed on human ears may lead to similar fibrosis needs to be considered and addressed.
Future strategies to minimize risks
The short-and long-term risks associated with inner ear drug delivery may be further minimized by future technological or procedural developments. For example, optimization of drug delivery catheter design and size may help minimize intracochlear trauma and the size of the round window membrane/cochleostomy fenestration, which would reduce the risk of perilymph fistula. Similarly, the use of a minimally traumatic intracochlear catheter may allow for drug delivery to the more apical regions of the cochlear duct. In addition, a more potent biological effect could be obtained with the combination of a mini-osmotic pump for sustained delivery of the bioactive agent.
Another method to decrease the risk of intracochlear trauma and its downstream effects would be to curtail intracochlear pressure spikes upon infusion. Large intracochlear pressure spikes equivalent to a sound exposure of 115 dB have been demonstrated in studies of cochlear implant electrode insertion (Greene et al., 2016) . Similar intracochlear pressure elevation could potentially be encountered with inner ear drug delivery. Robotic surgery is a promising method to minimize the risk of intracochlear trauma during cochleostomy, drug infusion, and device placement. Using preoperative high-resolution computed tomography for surgical planning and intraoperative navigation, the precise trajectory required for cochlear access can be planned by the surgeon, resulting in a minimally invasive surgical approach that minimizes trauma to the endosteal membrane and other cochlear tissues (Brett et al., 2007; Coulson et al., 2008; Majdani et al., 2009) . In a comparison of manual versus robotic cochleostomy, there are significantly less intracochlear pressure disturbances using a robotic micro-drill Coulson et al., 2013; Dillon et al., 2016) . A minimally traumatic cochleostomy can be achieved using an automatic or semi-automatic robotic drill, hand-guided robotic drill, or with laser (Brett et al., 2014; Hussong et al., 2008; Wimmer et al., 2014; Zhang et al., 2014) . Robotic cochlear implant electrode insertion has also been validated in cadaveric models, demonstrating minimal insertion trauma and successful insertion in the majority of cases (McRackan et al., 2013; Schurzig et al., 2012; Venail et al., 2015) . A robotic approach for cochlear implant insertion has already been tested in nine patients, with six radiographically confirmed insertions (Labadie et al., 2014) . Unfortunately, one patient had permanent facial paralysis with this technique, which highlights the need for further refinement of targeting strategies prior to safe application of a robotic approach in cochlear implant insertions and other otological procedures. Further studies are required to refine the technique and test its broader applicability to a larger number of patients. Similarly, a robotic-assisted method for drug infusion and device placement could help mitigate the potentially damaging effects of intracochlear trauma.
With the refinement and increased availability of higher magnet strength MRI scanners, it may become possible to perform high resolution imaging of the cochlea after drug delivery. When paired with contrast administration, this could potentially identify evolving inner ear inflammation after drug delivery to enable prompt treatment with steroids and/or other anti-inflammatory medications, thereby reducing the risk of downstream adverse events.
In summary, there are numerous potential short-and long-term risks of inner ear drug delivery in clinical settings. Existing knowledge of how to minimize these risks, gained over decades of experience with stapedotomy and cochlear implantation, will be invaluable as novel inner ear biologics become a reality. In addition, novel technological developments in catheter design, microinfusion pumps, robotic surgery, and high-resolution cochlear imaging may also provide alternative methods to ensure safety and optimize the efficacy of inner ear drug delivery in the future.
Conclusions
1. Inner ear delivery of a wider variety of reagents will provide a much broader range of treatment possibilities for otologic conditions. 2. There are several routes of delivery to the inner ear, most classically via a transtympanic or intracochlear approach, but many additional possibilities are being explored in animal models, including intralabyrinthine injections in various locations and direct injection into the scala media. 3. Many innovations in technology including optogenetics, cellspecific targeting, increased viral vector specificity, sequential drug-device combinations, gene editing, gene therapy using suicide genes and immunotherapy may be applied to the inner ear in the future. 4. Safer drug delivery may be accomplished with automated approaches such as robotic surgery and micro-infusion pumps, as well as with improved high-resolution imaging modalities for the inner ear. 5. In order to maximize potential therapies for the inner ear, future studies are needed to better understand the etiology of inner ear disorders such as M eni ere's disease and sudden sensorineural hearing loss, and to improve diagnostics of the condition of the cochlear cells, with details about their presence and functionality.
